List of clinical trials
The Centre Rétine Gallien offers access to innovative treatments as part of its Clinical Research activity.
- Research carried out on humans is subject to a legal framework.
- In all cases, confidentiality and data security are guaranteed.
Currently being recruited
Phase 2 pilot study evaluating the efficacy of a treatment protocol involving loading dose injection of a dexamethasone implant in patients with diabetic macular edema.
- Treatment : Ozurdex
Recruitments completed
Vein occlusion
Randomised, double-blind, controlled, phase 3 study to evaluate the efficacy and safety of aflibercept 8 mg in macular oedema secondary to retinal vein occlusion.
Study treatment: Aflibercept 8mg
Inclusions in the centre – 3 patients
Phase III, multicentre, randomised, double-blind, two-arm, 18-month study to evaluate the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to macular oedema secondary to retinal vein branch occlusion.
Study treatment: Brolucizumab – BEOVU®.
Inclusions in the centre – 9 patients
AMD atrophic
Study of disease progression in genetically defined patients with geographic atrophy secondary to age-related macular degeneration.
Study treatment: NA
Inclusions in the centre – 67 patients
AMD wet
A 64-week, randomised, double-blind, parallel-group, multicentre phase IIIb study evaluating the efficacy and safety of brolucizumab 6mg compared to aflibercept 2mg in a ‘treat to control’ regimen in patients with neovascular age-related macular degeneration.
Study treatment: Brolucizumab – BEOVU®.
Inclusions in the centre – 10 patients
A multicentre, randomised, double-blind, dose-ranging study to assess the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration.
Study treatment: Conbercept
Inclusions in the centre – 3 patients
Diabetic oedema
Multicentre, randomised, double-blind, two-year, two-arm phase III study comparing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular oedema.
Study treatment: Brolucizumab – BEOVU®.
Inclusions in the centre – 4 patients
Cataract Surgery
Prospective, multicentre, non-comparative clinical investigation to evaluate the safety and efficacy of the I.SPACE® viscoelastic ophthalmic device.
Study treatment: I.SPACE® viscoelastic ophthalmic device
Inclusions in the centre – 23 patients
Randomized clinical investigation of viscoelastic ophthalmic device.
Sponsor = Laboratoire LCA
Treatment = viscoelastic IXIUM HCS vs DUOVISC
Intended for cataract surgery with intraocular implant placement.
Sponsor = Laboratoire LCA
Treatment = viscoelastic IXIUM HCS vs DUOVISC
Choroidal melanoma
Prevention of neovascular glaucoma by intravitreal anti-VEGF injections in patients treated with proton therapy for large choroidal melanoma
Study treatment: aflibercept 2mg
Inclusions in the centre – 4 patients